Nicotine Lozenge to Reduce Smokeless Tobacco Use

• Status: Completed
• Trial end date: 2007-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Smokeless tobacco (ST), which includes both chewing tobacco and snuff, has as many health risks associated with its use as cigarettes. While there are many treatment programs that focus on stopping tobacco use, there are no interventions that specifically focus on reducing tobacco use. This study will evaluate the effectiveness of nicotine lozenge at reducing tobacco use in ST users.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: National Institute on Drug Abuse (NIDA)
• Collaborators: University of Minnesota; University of Minnesota - Clinical and Translational Science Institute
• Treatments: Lobeline; Nicotine

Criteria

Inclusion Criteria:

• No interest in stopping ST use within 90 days of study entry

• Using ST at least 6 times a day in the 6 months prior to study entry

• Willing to use contraception throughout the study

Exclusion Criteria:

• Current use of tobacco or nicotine products, other than ST

• Current unstable medical condition

• Use of any medication that may affect tobacco use or be affected by a reduction in tobacco use

• Meets DSM-IV diagnostic criteria for any psychiatric disorder or substance abuse disorder within 6 months of study entry

• Use of any psychotropic medication within 6 months of study entry

• Pregnant or breastfeeding